Crofelemer for Short Bowel Syndrome
This study is looking at an oral medication called crofelemer for adults with Short Bowel Syndrome (SBS) who have had their colon removed and rely on parenteral support (IV nutrition). The goal is to see if crofelemer can help reduce the amount of fluid coming out of your ostomy (ostomy output) or lessen your need for IV nutrition. You would take crofelemer powder three times a day for 12 weeks, followed by a 4-week observation period. This is a small pilot study, aiming to enroll 6 participants, to understand how well crofelemer works and if it is safe.
- Study design
- This is an open-label pilot study, meaning both you and the study team will know you are receiving crofelemer. It plans to enroll 6 participants.
- What's involved
- You would take crofelemer powder three times daily for 12 weeks. There will also be a 4-week follow-up period after treatment.
- Compensation
- Not stated in the trial record.
- Follow-up
- Participants will be followed for 4 weeks after the 12-week treatment period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Open-Label Pilot Study With Crofelemer in Patients With Short Bowel Syndrome
At a glance
Conditions
NCT06326645
Where you'd take part
This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Cleveland Clinic Main Campus
Cleveland, Ohiono site contact published
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Lindsey Russell · PRINCIPAL_INVESTIGATOR · The Cleveland Clinic
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
What this trial measures
- Ostomy output reduction12 weeks
Change in ostomy output from baseline over the entire 12-week treatment period as average weekly ostomy output at week 12.